Clinical Research Directory
Browse clinical research sites, groups, and studies.
LUPKYNIS Drug-use Results Survey
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2025-09-17
Completion Date
2032-06-30
Last Updated
2025-09-19
Healthy Volunteers
No
Conditions
Interventions
Voclosporin (LUPKYNIS)
In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.
Locations (1)
Pharmacovigilance Department
Osaka, Osaka, Japan